【摘要】 目的探讨尼莫地平联合艾地苯醌治疗脑梗死恢复期效果及对患者S-100β蛋白、P选择素表达的影响。方法将105例脑梗死恢复期患者按照简单随机化分组方法分为3组,各35例。对照A组给予尼莫地平治疗,对照B组给予艾地苯醌治疗,联合组给予尼莫地平联合艾地苯醌治疗,观察4周。采用美国国立卫生研究院卒中量表评定3组患者的临床疗效,比较治疗前后3组纤维蛋白原、血小板黏附率、血细胞比容水平及血清S-100β蛋白、P选择素水平。比较治疗前后3组中国脑卒中临床神经功能缺损程度评分量表、肢体运动功能评分及日常生活活动能力量表评分。比较3组不良反应发生率。结果3组患者临床疗效比较差异有统计学意义(P<0.05),联合组治疗总有效率最高。治疗后3组纤维蛋白原、血小板黏附率及血细胞比容水平均显著低于治疗前(P<0.01),3组间比较差异有统计学意义(P<0.01)。治疗后3组血清S-100β蛋白及P选择素水平均显著低于治疗前(P<0.01),3组间比较差异有统计学意义(P<0.01)。治疗后3组日常生活活动能力量表及Fugl-Meyer评分均较治疗前显著升高(P<0.01),中国脑卒中临床神经功能缺损程度评分量表评分较治疗前显著降低(P<0.01),3组间比较差异有统计学意义(P<0.01)。3组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论尼莫地平联合艾地苯醌治疗脑梗死恢复期患者疗效显著,可下调血清S-100β蛋白、P选择素水平,改善血液流变学指标及运动功能,恢复神经功能,提高日常生活能力,且安全性较高。更多还原

【Abstract】 Objective To explore the effect of nimodipine combined with idebenone in the treatment of patients with cerebral infarction in the recovery period and the effect on the level of S-100βprotein sP-selectin.Methods A total of 105 patients with cerebral infarction(CI)in the recovery period were randomly divided into 3 groups,35 cases each.The control group A was given nimodipine treatment,the control group B was given idebenone treatment,and the combination group was given nimodipine combined with idebenone treatment,and the observation was 4 weeks.National Institute of Health stroke scale(NIHSS)was used to evaluate the clinical efficacy of the three groups of patients before and after treatment.The fibrinogen(FIB),platelet adhesiveness(PAR),red blood cell specific volume(Hct)level and serum S-100βprotein and sP-selectin level were compared before and after treatment.The Chinese Stroke Scale for the degree of clinical Neurological Impairment(CSS),Fugl-Meyer(FM)and activity of daily living(ADL)scores of the three groups before and after treatment were compared.Compare the incidence of adverse reactions in the 3 groups.Results The difference in clinical efficacy among the 3 groups of patients was statistically significant(P <0.05),and the combined group had the highest overall effective rate of treatment.After treatment,the levels of FIB,PAR and Hct in the three groups were significantly lower than before treatment(P<0.01),and the difference between the three groups was statistically significant(P<0.01).After treatment,the levels of serum S-100βprotein and sP-selectin in the three groups were significantly lower than before treatment(P<0.01),and the difference among the three groups was statistically significant(P<0.01).After treatment,the ADL and Fugl-Meyer scores of the three groups were significantly higher than those before the treatment(P<0.01),and the CSS scores were significantly lower than that before the treatment(P<0.01).The difference among the three groups was statistically significant(P<0.01).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusions Nimodipine combined with idebenone has a significant effect in the treatment of patients with cerebral infarction in the recovery period.It can down-regulate serum S-100βprotein and sP-selectin,improve blood rheology indexes and motor function,restore nerve function,and improve the ability of daily living,and the safety is high.更多还原